IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: WHITTAKER

Title: METHODS AND

COMPOSITIONS FOR MEASURING BIOLOGICALLY

ACTIVE NATRIURETIC
PEPTIDES AND FOR
IMPROVING THEIR

THERAPEUTIC POTENTIAL

Appl. No.: 10/645,874

Filing Date: August 20, 2003

Examiner: Lum

Art Unit: 1641

Confirmation 8658

Number:

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR \$1.56

Mail Stop Amendment-IDS Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicant in order to comply with Applicant's duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a prima facie art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b). before the mailing date of the first Office Action on the merits after the filing of a Request for Continued Examination.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicant respectfully requests that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP 8609.

Although Applicant believes that no fee is required for this Request, the Commissioner is hereby authorized to charge any additional fees which may be required for this Request to Deposit Account No. 19-0741.

Respectfully submitted,

Date 07/24/2007 FOLEY & LARDNER LLP

Customer Number: 30542 Telephone: (858) 847-6722

Facsimile: (858) 792-6773

Barry S. Wilson

Attorney for Applicant Registration No. 39,431 Approved for use through 03/31/2007, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute for form	1449/	PTO		Complete if Known	
	INFORMATION DI	SCLO	SURE	Application Number	10/645,874	
	STATEMENT BY A	APPLI	CANT	Filing Date	August 20, 2003	
				First Named Inventor	Whittaker	
				Art Unit	1641	
	(use as many sheets	as ne	cessary)	Examiner Name	Lum	
Sheet	1	of	2	Attorney Docket Number	071949-7002	

			U.S. PATENT DO	CUMENTS		
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant	
Initials*	No.1	Number-Kind Code ² (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear	
	A1	6828107	12-07-2004	Asada et al.		
	A2	2005/0181386	08-18-2005	Diamond et al.		
	A3	6117644	09-12-2000	DeBold		
	A4	2005/0244902	11-03-2005	Gotze et al.		

	UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS						
Examiner Initials*	Cite No.1	U.S. Patent Application Document Serial Number-Kind Code ² (if known)	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		

			FOREIGN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	A5	WO 00/052476	09-08-2000	Skye Pharmatech Incorporated		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T⁵
	A6	Cala, Computerized axial tomography in the detection of brain damage. Medical Journal of Australia, 2(11): 616-620, 1980.	
	A7	Cuzzocrea et al., Effects of tempol, a membrane-permeable radical scavenger, in a gerbil model of brain injury. Brain Research, 875:96-106, 2000.	
	A8	Griffin et al., The inhibition of myeloperoxidase by ceruloplasmin can be reversed by anti-myeloperoxidase antibodies. Kidney International, 55:917-925, 1999.	

Examiner	Date
Signature	Considered
*EYAMINER: Initial if reference considered, whether or not citation	a is in conformance with MOCD COD. Deep the short of the state of the

"EXAMINES: Initial infederace considered, whether or not obtain is in conformance with MEEP 059. Draw like through classion if not in conformance and not considered.

Initialized poly of like from with mast communication 1-by against value, a better obtaining horizon number of problem. If see fixed is class or USPTO internot Concurrent as town uspits open or MEEP 901.04.3 Sincer Office that issued the document, by the tor-clear code (MEO Standed ST.3), 4 For Japanese patient document, by the tor-clear code (MEO Standed ST.3), 4 For Japanese patient document, by the tor-clear code (MEO Standed ST.3), 4 For Japanese patient document, by the tor-clear code (MEO Standed ST.3), 4 For Japanese patient document, by the source of the part of the propriet symbols as indicated on the document of the year of the region of the Company of the propriets symbols as indicated on the document of the part of the propriets symbols as indicated on the document of the propriets symbols as indicated on the document of the propriets symbols as indicated on the document of the part of the propriets symbols as indicated on the document of the propriets symbols as indicated on the document of the propriets symbols as indicated on the document of the propriets symbols as indicated on the document of the propriets symbols as indicated on the document.

In the propriets of the propriets symbols are considered in the document of the propriets symbols as indicated on the document of the propriets symbols as indicated on the document of the propriets symbols as indicated on the document of the propriets symbols as indicated on the document of the propriets symbols as indicated on the document of the propriets symbols as indicated on the document of the propriets symbols as indicated on the document of the propriets symbols as indicated on the document of the propriets and the propriets of the propriets and the propriets symbols are symbols as indicated on the document of the propriets and the propriets are symbols as indicated on the document

process) an application. Confidentiality is governed by 35 U.S. C. 122 and 37 CFR 1.4c. This collection is estimated by law 2 hours 1 commission of the comm

Approved for use through 03/31/2007, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

$\overline{}$	Substitute for form	1449/	PTO	Complete if Known		
	INFORMATION DI	SCLO	SURE	Application Number	10/645,874	
	STATEMENT BY	APPLI	CANT	Filing Date	August 20, 2003	
				First Named Inventor	Whittaker	
				Art Unit	1641	
	(use as many sheets	as ne	cessary)	Examiner Name	Lum	
Sheet	2	of	2	Attorney Docket Number	071949-7002	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	A9	Minota et al., Circulating myeloperoxidase and anti-myeloperoxidase antibody in patients with vasculitis. Scand J Rheumatol, 28:94-99, 1999.	
	A10	Montaner et al, Matrix metalloproteinase expression after human cardioembotic strike. Stroke, 32:1759-1766, 2001	
	A11	Stronglin, Laboratory diagnosis of viral infections, sensitivity, specificity, and predictive value of diagnostic tests: Definitions and clinical applications. Lennette et al. eds., New York: Marcel Dekker, Inc., p. 211-219, 1992.	
	A12	Tervaert, The value of serial ANCA testing during follow-up studies in patients with ANCA-associated vascultides: A review. Journal of Nephrology, 9(5): 232-240, 1996.	

Examiner	Date Considered
Signature	Considered

[&]quot;EXAMINE: Initial if reference considered, whether or not catation is in conformance with MFEP 600. Draw line through clastics in fig. of not in conformance and not considered, include copy of this form with next communication to applicant. I Applicant is required instantine (spiral policy and policy and the property of the property

This collection of information is required by 37 CR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (end by the USPTO to produce a property of the public which is to file (end by the USPTO to produce a property of the public which is to file (end by the USPTO to produce a public which is to direction is estimated to take 2 hours to to ampoint, including partnering, repearing, and submitting the incompleted application form to the USPTO. The well vary depending upon the individual case. Any comments on the amounted the public completed this form and/or suggestions for reducing this source, should be sent to the Chief Information Officer, U.S. Pattert and Trademark Office, P.O. Box 1450, Alexandria, V.A. 20231-1450, D. Comments of the public view of the view of the public view of the public view of the public view of the public view of the view of the